Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A vaccine to prevent gonorrhoea and combat spread of AMR targeting LMICs



Neisseria gonorrhoeae (gonococcus) causes 82.4 million cases of the sexually transmitted infection, gonorrhoea, annually with women in low- and middle-income countries (LMICs) disproportionately affected. Complications include pelvic inflammatory disease, ectopic pregnancy, infertility, and infant blindness. Rapid emergence of multi-drug resistant gonococci threatens to make these infections untreatable. The need for a gonococcal vaccine is pressing, but currently none is available.


Map showing distribution of gonorrhea worldwide. Source: WHOMap showing distribution of gonorrhea worldwide. Source: WHO



We are using native outer membrane vesicle (nOMV) technology to develop a candidate vaccine against gonococcus, GonoVac. The vaccine is immunogenic and able to accelerate the clearance of gonococcus in a preclinical infection model. We are currently conducting bioprocess studies and analytical development leading to the production of Good Manufacturing Practice (GMP)-quality vaccine lots for testing in humans. In parallel, we are investigating clinical samples from patients with gonorrhoea to understand the mechanisms of immunological protection against gonorrhoea and correlates of projection.




 Read more about the project funding here 



Christine Rollier

Prof Christine Rollier | University of Surrey


 Peter Beernink


Sanjay Ram



Our team